Preclinically, AZD8186 has fairish activity across tumour cells and PTEN-null tumour models (Lynch et al. 2017) alone or in combination with docetaxel (Hancox et al. 2015), androgen deprivation (Marques et al. 2015), PI3Kα inhibitor (Schwartz et al. 2015) and mitogen-activated protein kinase kinase (MEK) inhibitor (Marques et al. 2020). This evidence concerns the gene WNK2 and neoplasm.